Bimekizumab in plaque psoriasis: Efficacy across subgroups in phase III/IIIb trials

Results from a post hoc analysis of the phase III/IIIb BE SURE (NCT03412747), BE VIVID (NCT03370133), BE READY (NCT03410992), BE BRIGHT (NCT03598790), and BE RADIANT (NCT03536884) trials, evaluating bimekizumab efficacy across subgroups in patients with moderate-to-severe plaque psoriasis, were published by Strober et al. in Dermatology and Therapy. The primary outcome was the proportion of patients who achieved Psoriasis Area and Severity Index (PASI) 100.

Key data: Among patients receiving continuous bimekizumab treatment for 3 years (N = 1,107), PASI 100 response rates remained consistent across subgroups, including age (40 to <65 years vs ≥65 years [68.6% vs 73.7%]), male vs female (69.6% vs 71.4%), weight (≥103.9 kg vs <74.3 kg [63.4% vs 75.5%]), disease duration of ≤5 vs >20 years (65.5% vs 71.1%), disease severity (PASI 12 to <15 vs PASI ≥20 [67.7% vs 71.1%]), nail involvement vs no involvement (69.1% vs 71.3%), prior biologic exposure vs no exposure (71.7% vs 69.1%), and prior anti-tumor necrosis factor (TNF) exposure vs no exposure (67.6% vs 70.6%).

Key learning: Bimekizumab demonstrated consistently high long-term efficacy in patients with plaque psoriasis across diverse subgroups, highlighting bimekizumab as an effective treatment for this patient population.